ITSA4:BMFBOVESPAItausa SA Non-Cum Perp Pfd Registered Shs Analysis
Data as of 2026-03-13 - not real-time
R$13.20
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
ITSA4 is trading at R$13.20, below its 20‑day (R$14.11) and 50‑day (R$13.43) simple moving averages, indicating short‑term pressure, while the 200‑day SMA (R$11.59) remains under the price, supporting a longer‑term bullish bias. The RSI sits at 40, suggesting the stock is not yet oversold, and the MACD histogram is negative with a bearish signal line, reinforcing the near‑term downside momentum. Volume has been decreasing, and the current price hovers just above the identified support level of R$13.11, with resistance near R$15.12. Volatility over the past 30 days is high at roughly 31.6%, yet the beta of 0.35 points to low systematic risk relative to the market. Valuation metrics are compelling: the trailing P/E of 9.6 is far below the industry average of 29.1, and the price‑to‑book of 1.6 reflects modest premium to net assets. Despite the attractive multiples, the company carries a very high debt‑to‑equity ratio of 11.4 and negative operating and free cash flow, raising concerns about financial flexibility. The dividend yield of 0.73% is modest and the payout ratio of 72% may be hard to sustain given cash‑flow constraints. Analysts rate the stock as a strong buy, with a median target price of R$15.45, implying roughly 17% upside from today’s level. The market sentiment index is in “Greed” territory (72.77), indicating bullish investor mood. However, the combination of high leverage, declining volume, and bearish short‑term technical signals tempers enthusiasm. In summary, the stock appears undervalued on a valuation basis but faces medium‑term risk from debt and cash‑flow pressures, while the diversified conglomerate structure offers a defensive long‑term profile.
The upside potential and strong analyst endorsement support a medium‑term buying case, yet investors should monitor the debt load, cash‑flow generation, and any regulatory shifts affecting its financial and infrastructure businesses. A cautious stance—holding now with a view to add on potential dips—balances the attractive valuation against the highlighted risks.
The upside potential and strong analyst endorsement support a medium‑term buying case, yet investors should monitor the debt load, cash‑flow generation, and any regulatory shifts affecting its financial and infrastructure businesses. A cautious stance—holding now with a view to add on potential dips—balances the attractive valuation against the highlighted risks.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical support
- Bearish MACD and decreasing volume
- High leverage and negative cash flow
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation gap vs industry
- Analyst consensus strong‑buy and 17% upside target
- Low beta and diversified business model
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Diversified conglomerate reduces sector concentration risk
- Sustainable ROE despite cash‑flow challenges
- Potential regulatory and debt‑service pressures
Key Metrics & Analysis
Financial Health
Revenue Growth-5.00%
Profit Margin193.63%
P/E Ratio9.6
ROE17.06%
ROA0.19%
Debt/Equity11.41
P/B Ratio1.6
Op. Cash FlowR$-134000000
Free Cash FlowR$-1618749952
Industry P/E29.1
Technical Analysis
TrendBullish
RSI40.1
SupportR$13.11
ResistanceR$15.12
MA 20R$14.11
MA 50R$13.43
MA 200R$11.59
MACDBearish
VolumeDecreasing
Fear & Greed Index72.77
Valuation
Target PriceR$15.48
Upside/Downside17.25%
GradeUndervalued
TypeBlend
Dividend Yield0.73%
Risk Assessment
Beta0.35
Volatility31.64%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.